Survey to improve communication about radioligand therapy - The PEARLT Survey
Navigating cancer treatment is a challenging journey, and we would be honored if you would share your experience with us.
What is the PEARLT Survey?
To bridge this gap, RLT4BE has launched the Patient Education & Awareness on RLT Survey (PEARLT Survey) to assess patients' awareness and challenges across Belgium. The insights gathered will help improve education and awareness efforts for current and future patients.
Who should participate?
We invite Belgian cancer patients who are about to receive or have received Lutetium-177 PSMA for advanced prostate cancer or Lutetium-177 DOTATATE for neuroendocrine tumors, as well as their caregivers, to take part in this important survey.
Make a difference in the future of RLT for cancer care in Belgium by taking this survey:
Every response is valuable. By sharing your perspective, you will contribute to better care and a more supported community for everyone affected by this disease.
--
For any doubts regarding the survey's questions, objectives or progress, feel free to contact the Oncidium foundation at contact@oncidium-life.org.
RLT4BE is a government-supported action plan that brings together multiple stakeholders to prepare Belgium for the future of radioligand therapy in cancer treatment.
